In contrast, approximately 74% of semaglutide users may encounter some unwanted side effects
Caution is warranted in individuals with a history of pancreatitis or thyroid carcinoma, and close monitoring for potential cardiovascular risks is essential, particularly in high-risk populations
Your healthcare provider will assess whether Wegovy is appropriate for you based on several factors, including your body mass index (BMI), the presence of weight-related comorbidities, and your overall health status
Medication such as tirzepatide can offer better weight loss outcomes, whereas orlistat or Qsymia would be cheaper options
However, Wegovy has shown slightly more effectiveness in terms of weight loss in some studies, with patients losing an average of 15% of their body weight over 68 weeks compared to 10% for Ozempic users